Skip to Content


on Dean for unparalleled patient care and customer service.

Showing 1-9 of 9

Sorted By:

  • Breast Cancer - NSABP B-43

    Phase III clinical trial comparing Trastuzumab given concurrently with radiation therapy and radiation therapy alone for women with DCIS.

  • Breast Cancer - NSABP B-47

    Phase III trial of adjuvant therapy comparing chemotherapy alone to chemotherapy plus Trastuzumab in HER2-negative/high risk invasive breast cancer.

  • Breast Cancer - S1207

    Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy in patients with breast cancer.

  • Lymphoma - E2408

    3-arm, randomized clinical trial comparing three different therapies in people with follicular B-cell, non-Hodgkin Lymphoma, stage two, three, or four.

  • Lymphoma - PrE0401

    Phase II randomized trial comparing GA101 (Obinutuzumab) and Rituxan in patients with previously untreated low tumor burden indolent Non-Hodgkin’s Lymphoma.

  • Melanoma - Columbus Clinical Trial

    3-arm-open label, study of LGX818 plus MEK162 and LGX818 monotherapy compared with Vemurafenib in patients with unresectable or metastatic BRAF V600 mutation.

  • Melanoma - E1609

    Phase III, randomized study of adjuvant Ipilimumab versus high-dose Interferon a-2b for Resected High-Risk Melanoma.

  • Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia - S1117

    Phase II study of Azacitidine in combination with Lenalidomide vs.Azacitidine alone vs. Azacitidine in combination with Vorinostat for higher-risk MDS and CMML

  • Smoldering Myeloma - E3A06

    Randomized phase III clinical trial of Lenalidomide versus observation alone in patients with asymptomatic high-risk Smoldering Multiple Myeloma.

Showing trials 1-9 of 9

Dean Foundation

The clinical trials listed in this section are run by Dean Foundation, a non-profit organization, which works in partnership with the physicians of Dean Clinic. All Dean Foundation clinical trials are conducted in compliance with local, state and federal laws. All advertising materials are first approved by an Institutional Review Board that operates under regulation of the FDA and holds a Federalwide Assurance with the Office of Human Research Protections.

Learn more about the Dean Foundation and the work this organization does in the community.